These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21996202)

  • 1. Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors.
    Watorek E; Szymczak M; Boratynska M; Patrzalek D; Klinger M
    Transplant Proc; 2011 Oct; 43(8):2967-9. PubMed ID: 21996202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
    Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic disorders in renal transplant recipients].
    Mikolasević I; Jelić I; Sladoje-Martinović B; Orlić L; Zivcić-Cosić S; Vuksanović-Mikulicić S; Mijić M; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):235-41. PubMed ID: 23441539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New immunosuppressive therapies and surgical complications after renal transplantation.
    Barba J; Rosell D; Rincon A; Robles JE; Zudaire J; Berian JM; Pascual I; Errasti P
    Transplant Proc; 2012 Jun; 44(5):1275-80. PubMed ID: 22664000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
    Glotz D; Charpentier B; Abramovicz D; Lang P; Rostaing L; Rifle G; Vanrenterghem Y; Berthoux F; Bourbigot B; Delahousse M; Chalopin JM; Cassuto E; Lefrançois N
    Transplantation; 2010 Jun; 89(12):1511-7. PubMed ID: 20386144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
    Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T
    Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
    J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
    Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
    Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
    Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
    Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid status and kidney transplantation outcomes.
    Papalia T; Greco R; Lofaro D; Mollica A; Bonofiglio R
    Transplant Proc; 2011 May; 43(4):1042-4. PubMed ID: 21620048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we eliminate both calcineurin inhibitors and steroids?
    Lebranchu Y
    Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients.
    Mourer JS; de Koning EJ; van Zwet EW; Mallat MJ; Rabelink TJ; de Fijter JW
    Transplantation; 2013 Jul; 96(1):49-57. PubMed ID: 23715049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients.
    Mourer JS; Ewe SH; Mallat MJ; Ng AC; Rabelink TJ; Bax JJ; Delgado V; de Fijter JW
    Transplantation; 2012 Oct; 94(7):721-8. PubMed ID: 22955227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
    Zawiasa A; Nowicki M
    Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.